Category: 网络研讨会点播

Key Highlights:

此次付费教育讲座将介绍在美国、法国和德国获得市场准入和报销的流程，以及即将推出的联合临床评估 (Joint Clinical Assessment，JCA) 流程。In the US, we will be discussing the stakeholders that are involved in product access given the fragmented US payer system (e.g. Commercial, Medicare, … Continued

Nonclinical scientists in drug development have volumes of data to analyze and interpret. Visualization is a key tool in their toolbox, allowing for the detection of signals and outliers. SEND datasets are ideal for powering these visualizations. Learn how to turn this regulatory dataset into a engine for internal decision-making with SEND Explorer.

与安装在本地计算机上的 Phoenix 软件相比，Phoenix Hosted 为研究团队提供了更好的应用性能，可从 PC 或 Mac 环境灵活访问，并已预装、预授权和预验证。Phoenix Hosted 可在每个用户的个人工作区为任意数量的用户提供可扩展的硬件。Teams can quickly adopt the latest version … Continued

当一家制药公司面临产品专利期结束时，它就会遇到无数挑战，包括需要彻底改革其市场和销售策略。This session delves deep into these challenges, emphasizing how companies can pivot towards enhancing the marketing of their existing, patented products. The webinar will provide insights into … Continued

准备递交的 PK 分析面临着许多数据和合规方面的挑战。为了高效工作，分析人员需要一种方法和工具集，以便：与我们一起探索在安全的云托管环境中提供这些优势的工作流程。We’ll follow a non-compartmental analysis from end-to-end to highlight best practices for data preparation, modeling, and submission readiness. … Continued

Topics covered: 演讲嘉宾：Gilbert HunterCustomer Success ManagerPinnacle 21 by Certara Erin ErginerDirector of ProductPinnacle 21 by Certara

What does it take to industrialize QSP? What is the right mix of technology and domain expertise to integrate at scale? Join Certara’s Piet van der Graaf, formerly Applied BioMath’s John Burke and Joshua Apgar for insightful and interactive webinar as we share details of our vision for the next generation of QSP. Hear about … Continued

借助行业领导者的真知灼见，掌握临床阶段的转换！欢迎加入 QSP 高级副总裁兼负责人 Piet van der Graaf、QSP 神经科学建模负责人 Hugo Geerts、Certara 药物开发解决方案副总裁 Mirjam Trame 和 Certara 药物开发服务高级副总裁、药学博士 Julie M. Bullock 的行列。We are thrilled to welcome keynote speaker and panelist … Continued

Secondary pharmacology profiling involves the screening of small molecule compounds against a broad range of targets in order to try to predict off-target interactions leading to safety issues in humans. To date, this has generally required an opinion-based approach, but opinions vary and are inherently unreliable. To evaluate this quantitatively requires the use of surrogate … Continued